What is the 13F Pro Quality Score for INM?

13F Pro ranks InMed Pharmaceuticals Inc. (INM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INM's current score at https://13fpro.ai/company/INM (free sign-up required for the full ranking).

Where does 13F Pro source INM data?

All InMed Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. InMed Pharmaceuticals Inc. files with the SEC under CIK 1728328. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INM in?

InMed Pharmaceuticals Inc. (INM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INM research updated on 13F Pro?

INM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

InMed Pharmaceuticals Inc.(INM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1728328 INM stock profile & AI dashboard →

13F Pro Quality Score

20.9/100

Rank #2,771 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why INM Scores 21/100

exact factor attribution · 2026-09-11

INM's composite is driven by institutional flow, held back by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.5 pts

100th pct

Shareholder dilution

-0.4 pts

43th pct

Earnings quality

-1.3 pts

37th pct

Earnings growth

-2.2 pts

5th pct

Revenue growth

-3.9 pts

30th pct

Capital efficiency

-4.8 pts

3th pct

Free cash flow

-6.1 pts

9th pct

Profitability

-6.1 pts

9th pct

Scale

-6.8 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

INM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for InMed Pharmaceuticals Inc. (INM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INM at 20.9/100 on a 32-signal composite quality model, placing it at rank #2,771 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of INM by reported 13-F value include ADAR1 Capital Management, Vivo Capital, Squadron Capital Management, based on the most recent SEC filings. INM trades on the Nasdaq exchange and files with the SEC under CIK 1728328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InMed Pharmaceuticals Inc. directly from SEC EDGAR. InMed Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 13 and 21 since 2026, currently 20.9 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about InMed Pharmaceuticals Inc.

Quirks, history, and lore behind INM — the kind of stuff that makes a stock memorable.

1
The Basics
A Canadian biopharmaceutical company · micro-cap · listed on Nasdaq · headquartered in Vancouver, British Columbia.
2
The Numbers
With revenue in the low single-digit millions and a focus on early-stage development, this company is firmly in pre-profitability territory — the classic biotech burn.
3
The History
The company pivoted its research focus toward cannabinoid-based medicines, exploring the lesser-charted corners of pharmaceutical cannabis science rather than recreational markets.
4
The Secret
It operates a proprietary biosynthesis manufacturing platform designed to produce rare cannabinoids without the need to grow a single plant — chemistry over agriculture.
5
The Lore
Its lead programs target serious neurological conditions, including rare skin diseases like epidermolysis bullosa, putting cannabinoids to work where few pharma companies dare to go.
6
The Giveaway
A tiny Vancouver pharma pioneering pharmaceutical-grade rare cannabinoids via biosynthesis, trading under a three-letter ticker that starts with "INM" — no dispensary required.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-5.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2026

FY23 $4.1MFY24 $4.6MFY25 $4.9MFY26 —

Net Income

-53.9% YoY

$-12.6MFY 2026

FY23 $-7.9MFY24 $-7.7MFY25 $-8.2MFY26 $-12.6M

Operating Income

—FY 2026

FY23 $-7.9MFY24 —FY25 —FY26 —

EPS (Diluted)

+62.7% YoY

$-3.12FY 2026

FY23 $-3.25FY24 $-20.14FY25 $-8.36FY26 $-3.12

Total Assets

-80.6% YoY

$3.0MFY 2026

FY23 $14.1MFY24 $11.8MFY25 $15.6MFY26 $3.0M

Op. Cash Flow

-6.7% YoY

$-8.6MFY 2026

FY23 $-7.3MFY24 $-7.0MFY25 $-8.1MFY26 $-8.6M

Free Cash Flow

—FY 2026

FY23 $-7.4MFY24 $-7.0MFY25 $-8.1MFY26 —

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	$4.9M +7.5%	$4.6M +11.2%	$4.1M +279.6%	$1.1M -42.8%	$1.9M
Net Income	$-12.6M -53.9%	$-8.2M -6.3%	$-7.7M +3.4%	$-7.9M +57.3%	$-18.6M -82.3%	$-10.2M
Operating Income	—	—	—	$-7.9M +57.3%	$-18.6M -82.3%	$-10.2M
EPS (Diluted)	$-3.12 +62.7%	$-8.36 +58.5%	$-20.14 -519.7%	$-3.25 +80.4%	$-16.59 +12.6%	$-18.98
Total Assets	$3.0M -80.6%	$15.6M +31.8%	$11.8M -16.2%	$14.1M +10.3%	$12.8M +30.7%	$9.8M
Operating Cash Flow	$-8.6M -6.7%	$-8.1M -15.9%	$-7.0M +4.1%	$-7.3M +53.3%	$-15.6M -59.2%	$-9.8M
Free Cash Flow	—	$-8.1M -15.8%	$-7.0M +6.0%	$-7.4M +52.4%	$-15.6M -59.5%	$-9.8M

Get alerted when INM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for InMed Pharmaceuticals Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INM

ADAR1 Capital Management, LLC
$1.2M800,000 sh
Vivo Capital, LLC
$1.2M798,377 sh
Squadron Capital Management LLC
$503.8K325,000 sh
Ikarian Capital, LLC
$379.8K245,025 sh
Ursa Fund Management, LLC
$195.0K125,800 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$155.0K100,000 sh
BOOTHBAY FUND MANAGEMENT, LLC
$115.1K74,244 sh
SABBY MANAGEMENT, LLC
$69.7K44,970 sh
JANE STREET GROUP, LLC
$66.8K43,078 sh
VR Adviser, LLC
$50.7K32,685 sh

Fund	Value	Shares
ADAR1 Capital Management, LLC	$1.2M	800,000
Vivo Capital, LLC	$1.2M	798,377
Squadron Capital Management LLC	$503.8K	325,000
Ikarian Capital, LLC	$379.8K	245,025
Ursa Fund Management, LLC	$195.0K	125,800
SUVRETTA CAPITAL MANAGEMENT, LLC	$155.0K	100,000
BOOTHBAY FUND MANAGEMENT, LLC	$115.1K	74,244
SABBY MANAGEMENT, LLC	$69.7K	44,970
JANE STREET GROUP, LLC	$66.8K	43,078
VR Adviser, LLC	$50.7K	32,685

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INM on your watchlist

Track score changes the day InMed Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INM a good stock to buy?

13F Pro's AI-powered analysis of InMed Pharmaceuticals Inc. (INM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INM are available on the INM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INM is classified as a small company.

Which hedge funds own INM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of InMed Pharmaceuticals Inc.'s investment landscape.